Passage Bio, Inc. Overview
Pro stress-test →Passage Bio is a clinical-stage genetic medicines company focused on developing one-time therapies targeting the underlying pathology of neurodegenerative diseases. The lead product candidate, PBFT02, seeks to treat frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression.
Strategic Profile
Pro stress-test →Passage Bio delivered promising data in 2024 showing durable progranulin expression and completed development and scale-up of a high-productivity, suspension-based manufacturing process. The company benefits from strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program and partnership agreements with Catalent Maryland.
Competitive Landscape
Pro stress-test →Passage Bio competes in AAV gene therapy space with competitors including Sarepta Therapeutics focused on rare neurological diseases and CRISPR/Intellia Therapeutics developing gene therapies for severe rare neurological conditions. Passage Bio differentiates through focused CNS neurodegenerative disease portfolio and proprietary suspension-based manufacturing approach enabling potential dose flexibility.
Industry Context
Passage Bio, Inc. operates in Genetic Medicines / Gene Therapy - CNS Neurodegenerative Diseases.
Key facts
Founded: 2017 · Headquarters: Philadelphia, US · Employees: 65 · Revenue: $35M